Evidence map›Paper›PMID 35230142›Full record

Trial reportJournal of child and adolescent psychopharmacology2022

A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.

Ann C Childress, Eric Lloyd, Steven A Johnson, Lhanoo Gunawardhana, Valerie Arnold

Open access · hybridAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of child and adolescent psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ann C ChildressCenter for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, USA.ORCID 0000-0001-5782-7891
Eric LloydTakeda Pharmaceuticals USA, Inc., Bannockburn, Illinois, USA.
Steven A JohnsonTakeda Pharmaceuticals USA, Inc., Lexington, Massachusetts, USA.
Lhanoo GunawardhanaTakeda Pharmaceuticals USA, Inc., Bannockburn, Illinois, USA.
Valerie ArnoldCNS Healthcare, Memphis, Tennessee, USA.
Takeda (United States) · USCenter for Psychiatry and Behavioral Medicine · USCNS Healthcare · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChild, PreschoolDextroamphetamineDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansLisdexamfetamine DimesylateMaleTreatment OutcomeCentral Nervous System StimulantsDextroamphetamineLisdexamfetamine Dimesylateattention-deficit/hyperactivity disorderefficacylisdexamfetamine dimesylatepreschool-aged childrensafetytolerability

Identifiers

PMID35230142
PMCPMC8971990
OpenAlexW4214750643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.